Bridge Creek Capital Management LLC Buys 460 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bridge Creek Capital Management LLC grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,621 shares of the medical equipment provider’s stock after buying an additional 460 shares during the period. Bridge Creek Capital Management LLC’s holdings in Zimmer Biomet were worth $2,812,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of ZBH. Reinhart Partners LLC. increased its stake in Zimmer Biomet by 34.4% in the fourth quarter. Reinhart Partners LLC. now owns 86,755 shares of the medical equipment provider’s stock valued at $9,164,000 after purchasing an additional 22,220 shares in the last quarter. Thomasville National Bank increased its position in shares of Zimmer Biomet by 1.6% in the 4th quarter. Thomasville National Bank now owns 96,969 shares of the medical equipment provider’s stock valued at $10,243,000 after buying an additional 1,559 shares in the last quarter. Brookstone Capital Management raised its stake in Zimmer Biomet by 34.3% during the 4th quarter. Brookstone Capital Management now owns 8,581 shares of the medical equipment provider’s stock worth $906,000 after buying an additional 2,193 shares during the period. Czech National Bank lifted its holdings in Zimmer Biomet by 4.0% during the fourth quarter. Czech National Bank now owns 43,164 shares of the medical equipment provider’s stock worth $4,559,000 after acquiring an additional 1,678 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Zimmer Biomet by 8.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 15,845 shares of the medical equipment provider’s stock worth $1,710,000 after acquiring an additional 1,173 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on ZBH. Evercore ISI dropped their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Oppenheimer cut their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. Royal Bank of Canada increased their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Finally, Wells Fargo & Company boosted their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $123.33.

Zimmer Biomet Stock Performance

Shares of ZBH traded up $0.98 during mid-day trading on Monday, reaching $105.52. The company’s stock had a trading volume of 651,625 shares, compared to its average volume of 1,605,424. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a market cap of $21.01 billion, a P/E ratio of 20.06, a PEG ratio of 1.96 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.67 and a 1-year high of $133.90. The business has a 50-day simple moving average of $108.03 and a two-hundred day simple moving average of $108.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.65 earnings per share. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Monday, December 30th. Zimmer Biomet’s dividend payout ratio is 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.